Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17715175 | 1.00 | ARG1 (0.54) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL26116484 | 1.00 | ARG1 (0.54) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL25366838 | 1.00 | ARG1 (0.54) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL6122490 | 1.00 | ARG1 (0.54) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL26117849 | 0.98 | ARG1 (0.53) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL25361652 | 0.98 | ARG1 (0.53) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL25362592 | 0.98 | ARG1 (0.53) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL29035430 | 0.98 | ARG1 (0.53) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL22399152 | 0.85 | ARG1 (0.39) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL14979674 | 0.83 | CHRNB2 (0.39) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902693-B2 | Preparation method for pyrrolidine-2-carboxylic acid derivatives | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9809600-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3239153-A1 | 9-(1H-IMIDAZOL-5-YL)-1,11-DIHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HCV NS5A | Gilead Pharmasset LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2640719-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2935279-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2850085-B1 | ANTIVIRAL COMPOUNDS INHIBITORS OF HCV NS5A | GILEAD PHARMASSET LLC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2907816-A1 | Condensed imidazolylimidazoles as antiviral compounds | Gilead Pharmasset LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2635588-B1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014100500-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ARG1 3035/4885CYP1A2 4323/4885ALOX15 2615/4885 |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ARG1 3035/4885CYP1A2 4323/4885ALOX15 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.